Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 9/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30675640 | 0.98 | SMYD3 (0.53) | SMYD3ACKR3EPHX1HPGDSPOLB | |
| Hydrochloric Acid SCHEMBL30675644 | 0.98 | SMYD3 (0.53) | SMYD3ACKR3EPHX1HPGDSPOLB | |
| Acetic Acid SCHEMBL5502431 | 0.94 | SMYD3 (0.48) | SMYD3ACKR3EPHX1HPGDSPOLB | |
| SCHEMBL3944873 | 0.93 | SMYD3 (0.47) | SMYD3ACKR3EPHX1HPGDSHTR4 | |
| SCHEMBL5592779 | 0.90 | MAPK8 (0.44) | SMYD3 | |
| SCHEMBL4283681 | 0.87 | HPGD (0.49) | — | |
| SCHEMBL4705235 | 0.87 | GRM5 (0.48) | — | |
| SCHEMBL1876540 | 0.86 | HPGD (0.51) | — | |
| SCHEMBL4440234 | 0.86 | HPGD (0.51) | — | |
| SCHEMBL30332358 | 0.84 | HSD11B1 (0.47) | SMYD3HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049106-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-22 | — | — | EP | claimed |
| EP-2046327-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | claimed |
| EP-2046330-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | claimed |
| WO-2008009954-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-24 | — | — | WO | claimed |
| WO-2008007122-A2 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | claimed |
| WO-2008007113-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | claimed |
| CN-118726268-A | Methods for improving the efficacy and expansion of chimeric antigen receptor expressing cells | 诺华股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-108473957-B | Methods for improving the efficacy and expansion of chimeric antigen receptor expressing cells | 诺华股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-114008058-B | Prodrugs of CDK inhibitors for the treatment of cancer | 润佳（苏州）医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118221645-A | Proteolysis targeting chimeric and preparation method, pharmaceutical composition and application thereof | 河北康泰药业有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-114929345-A | Substituted pyrazole compounds as TOLL receptor inhibitors | 百时美施贵宝公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-3856262-A1 | COMBINATION THERAPY | Advanced Accelerator Applications (Italy) Srl (IT) | 2021-08-04 | — | — | EP | disclosed |
| EP-3826686-A1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | Advanced Accelerator Applications S.A. (FR) | 2021-06-02 | — | — | EP | disclosed |
| WO-2008007122-A2 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| EP-1845974-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1846393-A2 | 4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1845975-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077426-A2 | 4- (2, 6-DICHLOROBENZOYLAMINO) -lH-PYRAZOLE-3 -CARBOXYLIC ACID PIPERIDIN- 4 -YLAMID ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |